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Detroit, Michigan
Primary percutaneous coronary intervention (PCI) has be-
come the predominant reperfusion strategy for ST-segment
elevation myocardial infarction (STEMI) throughout west-
ern healthcare systems. Recent estimates in the United
States suggest that primary PCI is used in 85% of all
STEMI cases that undergo reperfusion, with thrombolytic
agents used in only 9% and the combination of thrombolytic
agents with PCI in 6% (1). This dramatic switch from
thrombolytic therapy to primary PCI was the result of
several studies conducted in the early 1990s that demon-
strated the superiority of primary PCI at reducing stroke
and reinfarction as well as an absolute reduction in mortality
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by 2% (2). These benefits were achieved despite a median
door-to-balloon time (D2BT) of 120 min in many of the
studies (3). The ability to achieve early and complete
reperfusion is important, with additional prognostic factors
including age, comorbidities, previous myocardial infarction
or congestive heart failure, and infarct size. Early reports
demonstrated that prolonged D2BTs were associated with
worse survival (4–7); however, little attention was paid to
the fact that sicker patients have more delay. Moreover, the
marked differences in survival could not have been due
simply to a delay in reperfusion (40% reduction in survival
with a 30-min delay) (4) because these mortality differences
were greater than what would be expected if the patient
never had reperfusion (8,9).
Because D2BT is easily determined, it quickly became a
measure of quality of care. Initiatives such as Mission
Lifeline and the D2B initiative, as well as widespread
education, publishing of individual hospital D2BTs, and its
use as a core measure of institutional quality, have dramat-
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argued that this intense focus on time to treatment has led to
less time spent in thoughtful diagnosis. Unfortunately, rapid
triage to the cath lab has contributed to misdiagnosis and
inappropriate treatment in a minority of suspected STEMI
cases. Furthermore, despite impressive reductions in
D2BTs, the mortality of patients undergoing primary PCI
has not fallen as much as expected. In fact, data from the
state of Michigan demonstrate that despite a 37-min
reduction in median D2BT from 113 to 76 min, mortality
remained unchanged at 4% (10). These observations high-
light the need to pause, reflect, and reconsider what options
may further benefit the STEMI patient.
One potential explanation for the less-than-expected
benefit with shorter D2BTs is that many patients who
undergo primary PCI are young, have small to moderate-
sized infarctions, and are treated more than 3 h from
symptom onset; these patients may not be expected to have
a mortality advantage from small improvements in time to
reperfusion (11). Conversely, many patients with delay in
reperfusion have high-risk features, such as diabetes, ad-
vanced age, heart failure, and respiratory distress (12), and
these factors cannot be altered by improvements in the
system of care.
In a paper in this issue of the Journal, a total of 82,678
STEMI patients enrolled in the National Cardiovascular
Data Registry were analyzed for nonsystem (e.g., patient)
delays (13). The data collection listed 4 possible reasons for
nonsystem delay. As expected, these delays were more
frequent in sicker patients (older, female, African American,
greater comorbidities) and were associated with a marked
increase in mortality (15.1% compared with 2.5% in primary
PCI patients without a nonsystem delay).
Clearly, one would not expect a 6-fold difference in
mortality with only a 30-min difference in the median
D2BTs (92 min vs. 63 min in patients without delay) (13).
Moreover, patients with cardiac arrest or who required
intubation had the highest mortality despite the shortest
D2BT (median: 84 min). The importance of this study is
that it demonstrates that delay, in and of itself, is probably
not responsible for huge differences in mortality. It is likely
a marker for higher risk patients, and the extent of risk is
difficult to ascertain in retrospective studies. However, the
frail nature of patients with nonsystem delay was further
demonstrated by the marked increase in noncardiac events
such as stroke, bleeding, vascular complications, and renal
failure; events that are not related to delay in reperfusion.
Unfortunately, this study is limited by its retrospective,
observational nature and the fact that 31% of the reasons for
nonsystem delay were unclassified (“other”). Key informa-
tion that may be useful in understanding these patients,
such as the time from chest pain onset to presentation, delay
in obtaining the electrocardiogram, and association with
other “system” delays, was not provided.
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some physicians to “game the system” by withholding
primary PCI in patients who are sick or who are anticipated
to have long D2BTs. Although these physicians may still
satisfy the core measure of reperfusion by giving thrombo-
lytic agents in this situation, this strategy may not be in the
patient’s best interest. Although we have dramatically short-
ened D2BTs and increased the proportion of STEMI
patients treated with primary PCI (instead of thrombolytic
therapy), the proportion of reperfusion-eligible STEMI
patients who are not treated has remained unchanged over
the past several years (14). To further improve prognosis,
physicians need to focus more on providing primary PCI to
more patients, especially the STEMI cases at highest risk.
We have come a long way in the management of the
STEMI patient, but we should not rest on our laurels.
Clearly, the worst prognosis is in patients in whom reper-
fusion therapy is withheld. As clinicians, we need to make a
concerted effort to provide early reperfusion to more pa-
tients. More widespread use of pre-hospital electrocardio-
grams, bypassing a non-PCI center in preference for a
tertiary care center, better public education about recogniz-
ing symptoms, and calling 911 are essential for continued
improvement in the management of all STEMI patients.
We hope that with advances in hemodynamic support,
methods to reduce reperfusion injury, systemic cooling of
the cardiac arrest patient, and stem cell myogenesis in the
setting of large infarction, the prognosis may be further
improved for those myocardial infarction patients at highest
risk.
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